Drug Trial Radar · NCT06143904
A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants
Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jun 3, 2009
Primary completion
Jul 5, 2009
Study completion Jul 5, 2009
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Objectives: To determine pharmacokinetic (PK) variables, including absolute bioavailability (F), of Genz-99067, the free base of the L-tartaric acid salt of Genz-112638 as it exists in plasma, after a single intravenous (IV) dose and after a single oral dose of Genz-112638 (unlabeled). To determine the PK, total recovery, routes and rates of excretion, and the metabolic profile of Genz-99067 after 5 days of BID oral dosing with unlabeled Genz-112638 followed by a single dose of \[14C\]-Genz-112638.
Conditions
- Gaucher's Disease Type I
Interventions
Genz-112638Drug
Pharmaceutical form:Solution-Route of administration:IV
Genz-112638Drug
Pharmaceutical form:Capsule-Route of administration:Oral
[14C]-Genz-112638Drug
Pharmaceutical form:Solution-Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of pharmacokinetic (PK) parameter: CmaxTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: TmaxTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: AUC0-∞Time frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: AUC0 -τTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: AUC0-∞/DTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: AUC0-τ/DTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: FTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: CL/FTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: t½Time frame: Multiple timepoints up to Day 26
- Pharmacokinetic (PK) parameter: Absolute bioavailability (F) of single-dose oral versus single-dose IV administrationTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: Total radioactivity excreted in urine and fecesTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: Total radioactivity in whole blood and plasmaTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: % relative abundance of each component in samples of plasma or excretaTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: The percentage of the administered dose attributed to each component in samples of urine or fecesTime frame: Multiple timepoints up to Day 26
- Assessment of pharmacokinetic (PK) parameter: The radioactivity of [14C]-Genz-99067 and each major metabolite in plasma, as identified by radio-profilingTime frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters: AUC0-tTime frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters: AUC0-∞Time frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters: CmaxTime frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters: TmaxTime frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters: t½Time frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters: Vz/FTime frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters: CL/FTime frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters for urine and feces: Cum AeTime frame: Multiple timepoints up to Day 26
- Noncompartmental PK parameters for urine and feces: % doseTime frame: Multiple timepoints up to Day 26
- Renal clearance (CLR) for total plasma radioactivity and Genz-99067Time frame: Multiple timepoints up to Day 26
- PK parameters [AUC0-τ, AUC0-∞, Cmax, Tmax, t½] and metabolite ratio for metabolite(s) of Genz-99067Time frame: Multiple timepoints up to Day 26
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.